Yi-Ching Wang
| Name/Title |
| Yi-Ching Wang chair professor& Director Department of Pharmacology |
| TEL |
| 886-6 235-3535 ext 06-2353535 ext 5502(O) / 5476(L) |
| FAX |
| 886-6 274-9296 |
| ycw5798@mail.ncku.edu.tw |
| Website |
|
| Education and Experience |
|
|
1993 PhD, Genetics, Michigan State University
1995 Associate Professor, Molecular Toxicology, Chung Shan Medical University
1999 Professor, Life Science, National Taiwan Normal University
2006 Distinguished Professor, Pharmacology, National Cheng Kung University
2015 Chair Professor, Pharmacology, National Cheng Kung University
|
|
| Research Interests | |
| ‧ |
Dr. Yi-Ching Wang’s laboratory has a long-standing research interest on the molecular mechanisms involved in tumorigenesis. Dr. Wang’s group investigates the etiological association of alterations in tumor suppressor genes and oncogenes in cancer signaling. Dr. Wang has continued to do research on cancer genomics and epigenomics of DNA methylation and chromatin alteration profiles for identification of new genes critical to lung tumorigenesis. Dr. Wang’s group identifies an oncogenic zinc finger transcription factor ZNF322A and investigates the underlying mechanisms of ZNF322A in cancer progression. More recently, Dr. Wang focuses on the role of Rab37 small GTPase in the regulation of exocytosis and malfunction of Rab37 in tumorigenesis and tumor microenvironment. Several potential anti-cancer drugs and immunomodulation antibodies are under development in my laboratory. Dr. Wang major research fields are listed below.
As a Principal Investigator for the last 30 years, Dr. Wang has published nearly 150 SCI papers [including prestigious journals such as Journal of Clinical Oncology, Journal of Clinical Investigation, Nature Communications, Advced Functional Materials, Nucleic Acids Research, Journal of Thoracic Oncology, Cancer Research, Clinical Cancer Research] on lung cancer and esophageal cancer with H-index of 46. In addition, her group has reported more than 300 conference papers, 4 book chapters, and obtained 4 Taiwan patents and 1 US patent (2 in application). |
| Published papers in referred journals | |
| 【Research NCKU】 | |
| Award |
|
| . | The Foundation for the Advancement of Outstanding Scholarship Award (2022-2024) |
| . | K. T. Li Honorary Scholar Award (2018) |
| . | Merit Research Fellow Award, Taiwan Ministry of Science (2017-2023) |
| . |
Dr. Wang Min-Ning Memory Foundation for Excellent Basic Medical Research award, Taiwan (2017) |
| . | E xcellent Research award of Taiwan Ministry of Science / National Science Council, Taiwan. (2004-2007, 2010-2013, 2014-2017) |
| Chair professor of National Cheng Kung University (2014-2017) | |
| . | Scientific paper award of Chinese Medical Association, Taiwan. (2013) |
| Excellent Research award in Pharmacology Society, Taiwan. (2008) | |
| Distinguished alumnus of Chinese Culture University, (2007) | |
| Ongoing projects | |
| . |
Investigation of Oct4-centered transcriptional networks in lung cancer progression and drug resistance. (MOST 103-2320-B-006-045-MY3) |
| . |
The vesicle trafficking and anti-tumorigenicrole of Rab37 small GTPase using lung cancer as a model. (MOST104-2320-B-006-047 - / MOST 105-2320-B-006-007-) |
| . |
Coordinate regulation of immune evasion in lung tumor microenvironment by Rab37 in infiltrating immune cells and WDR4 in tumor cells (MOST 106-2321-B-006-023 / MOST 107-2321-B-006-020) |
| . |
Targeting metabolic switch of lung cancer stem cells driven by ZNF322A transcription factor ( NHRI-EX107-10726BI) |